ShekarKRobertsJAMcdonaldCI, et al.Sequestration of drugs in the circuit may lead to therapeutic failure during extracorporeal membrane oxygenation. Crit Care. 2012;16(5):R194.
2.
ChengVAbdul-AzizMHRobertsJA, et al.Optimising drug dosing in patients receiving extracorporeal membrane oxygenation. J Thorac Dis. 2018;10(suppl 5):S629–S641.
3.
WiniszewskiHRougnyACLagoutte-RenosiJ, et al.The pharmacokinetic challenge of treating invasive aspergillosis complicating severe influenzae assisted by extracorporeal membrane oxygenation. Crit Care. 2018;22(1):355.
4.
RuizSPapyEDa SilvaD, et al.Potential voriconazole and caspofungin sequestration during extracorporeal membrane oxygenation. Intensive Care Med. 2009;35(1):183–184.
5.
Van DaeleRBrüggemannRJDreesenE, et al.Pharmacokinetics and target attainment of intravenous posaconazole in critically ill patients during extracorporeal membrane oxygenation. J Antimicrob Chemother. 2021;76(5):1234–1241.
6.
AshbeeHRBarnesRAJohnsonEM, et al.Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother. 2014;69(5):1162–1176.
7.
TheuretzbacherUIhleFDerendorfH, Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet. 2006;45(7):649–663.
